Breakthrough mRNA Cancer Vaccine Shows 67% Tumor Reduction in Phase 3 Trial
Moderna and Merck reported that their personalized mRNA cancer vaccine reduced tumor recurrence by 67% in advanced melanoma patients during a pivotal Phase 3 trial, potentially opening a new era in oncology treatment.
Moderna and Merck reported that their personalized mRNA cancer vaccine reduced tumor recurrence by 67% in advanced melanoma patients during a pivotal Phase 3 trial, potentially opening a new era in oncology treatment.
Related Articles
WHO Declares New Mpox Variant a Global Health Emergency
The World Health Organization activated its highest alert level after a new mpox variant showed increased transmissibility across 14 countries. Health agencies worldwide are accelerating vaccine distribution and surveillance protocols.
Dr. Amanda Foster·22h ago
Ozempic Maker Novo Nordisk Launches Next-Gen Weight Loss Drug With 25% More Efficacy
Novo Nordisk unveiled CagriSema, a combination therapy that showed 25.4% average weight loss in Phase 3 trials, surpassing current GLP-1 drugs. The company's market capitalization briefly exceeded $700 billion on the announcement.
Dr. Amanda Foster·23h ago
Comments(0)
No comments yet. Be the first to share your thoughts.